Malhan H, Dammag E, Alkahiry W, Ali G, Bahkali F, Alhakim A
Indian J Otolaryngol Head Neck Surg. 2024; 76(2):2104-2107.
PMID: 38566638
PMC: 10982179.
DOI: 10.1007/s12070-023-04429-2.
Chelysheva E, Apperley J, Turkina A, Yassin M, Rea D, Nicolini F
Leukemia. 2024; 38(4):788-795.
PMID: 38388649
PMC: 11408247.
DOI: 10.1038/s41375-024-02183-0.
Pinnenti M, Sami M, Hassan U
Biomicrofluidics. 2024; 18(1):011501.
PMID: 38283720
PMC: 10817778.
DOI: 10.1063/5.0172550.
Atallah E, Mauro M, Hochhaus A, Boquimpani C, Minami Y, Maheshwari V
J Cancer Res Clin Oncol. 2023; 149(9):6247-6262.
PMID: 36707445
PMC: 10356870.
DOI: 10.1007/s00432-022-04562-5.
Asif M, Hussain A, Wali A, Ahmed N, Ali I, Iqbal Z
Anal Cell Pathol (Amst). 2021; 2021:4909012.
PMID: 34422550
PMC: 8378985.
DOI: 10.1155/2021/4909012.
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
Hu B, Lin X, Lee H, Huang X, Slack Tidwell R, Ahn K
Leuk Lymphoma. 2020; 61(12):2811-2820.
PMID: 32662346
PMC: 8424781.
DOI: 10.1080/10428194.2020.1783444.
Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML.
Bugler J, Kinstrie R, Scott M, Vetrie D
Front Cell Dev Biol. 2019; 7:136.
PMID: 31380371
PMC: 6652210.
DOI: 10.3389/fcell.2019.00136.
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Cortes J, Gambacorti-Passerini C, Deininger M, Mauro M, Chuah C, Kim D
J Cancer Res Clin Oncol. 2019; 145(6):1589-1599.
PMID: 30989330
DOI: 10.1007/s00432-019-02894-3.
miR-140-5p induces cell apoptosis and decreases Warburg effect in chronic myeloid leukemia by targeting SIX1.
Nie Z, Liu X, Zhan Y, Liu M, Zhang X, Li Z
Biosci Rep. 2019; 39(4).
PMID: 30962263
PMC: 6488949.
DOI: 10.1042/BSR20190150.
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.
A First of Its Kind Study on CML Patients of Kashmir.
Azad N, Shah Z, Pandith A, Khan M, Rasool R, Rasool J
Asian Pac J Cancer Prev. 2018; 19(6):1479-1485.
PMID: 29936718
PMC: 6103580.
DOI: 10.22034/APJCP.2018.19.6.1479.
Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A, Stevenson M, Stevens J, Martyn-St James M, Hamilton J, Byrne J
Pharmacoeconomics. 2018; 36(8):903-915.
PMID: 29480454
DOI: 10.1007/s40273-018-0627-4.
A Study of Haemostatic Parameters in Patients of Chronic Myeloid Leukaemia.
Jain A, Gupta N, Singh T, Agarwal S
J Clin Diagn Res. 2016; 10(7):OC19-23.
PMID: 27630882
PMC: 5020258.
DOI: 10.7860/JCDR/2016/19185.8135.
Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.
Agatheeswaran S, Pattnayak N, Chakraborty S
Sci Rep. 2016; 6:32493.
PMID: 27586591
PMC: 5009428.
DOI: 10.1038/srep32493.
Bis-three-way junction nanostructure and DNA machineries for ultrasensitive and specific detection of BCR/ABL fusion gene by chemiluminescence imaging.
Xu Y, Bian X, Sang Y, Li Y, Li D, Cheng W
Sci Rep. 2016; 6:32370.
PMID: 27577607
PMC: 5006031.
DOI: 10.1038/srep32370.
Pancytopenia during tyrosine kinase inhibitor treatment - coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report.
Quixada A, Filho P, Filho T, Duarte F, Moreira-Nunes C, Goncalves Lemes R
J Med Case Rep. 2016; 10:207.
PMID: 27461416
PMC: 4962365.
DOI: 10.1186/s13256-016-0978-4.
Deletion 9p23 to 9p11.1 as sole additional abnormality in a Philadelphia positive chronic myeloid leukemia in blast crisis: a rare event.
Wafa A, Asaad M, Ikhtiar A, Liehr T, Al-Achkar W
Mol Cytogenet. 2015; 8:59.
PMID: 26244056
PMC: 4523925.
DOI: 10.1186/s13039-015-0165-0.
Rapid Identification and Verification of Indirubin-Containing Medicinal Plants.
Hu Z, Tu Y, Xia Y, Cheng P, Sun W, Shi Y
Evid Based Complement Alternat Med. 2015; 2015:484670.
PMID: 26089942
PMC: 4451998.
DOI: 10.1155/2015/484670.
First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.
Gugliotta G, Castagnetti F, Apolinari M, Pirondi S, Cavo M, Baccarani M
Drugs. 2014; 74(6):627-43.
PMID: 24711014
DOI: 10.1007/s40265-014-0207-7.
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Jabbour E, Cortes J, Kantarjian H
Expert Rev Anticancer Ther. 2013; 13(12):1433-52.
PMID: 24236822
PMC: 4181370.
DOI: 10.1586/14737140.2013.859074.
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J
Leukemia. 2012; 27(4):803-12.
PMID: 23238589
PMC: 3703612.
DOI: 10.1038/leu.2012.313.
